TP53 and myelodysplastic syndrome: As boundaries between AML and MDS fade in current classifications [38], recent data indicate that TP53-mutated AML and MDS with excess blasts share similar characteristics and prognoses, suggesting they should be regarded as a specific molecular disease entity [112,113,114].